Thu, June 5, 2025
Wed, June 4, 2025
[ Yesterday Afternoon ] - fox17online
Entertainment News: June 4, 2025
Tue, June 3, 2025
Mon, June 2, 2025
Sun, June 1, 2025
Sat, May 31, 2025
Fri, May 30, 2025
Thu, May 29, 2025
Wed, May 28, 2025
Tue, May 27, 2025
Mon, May 26, 2025
Sun, May 25, 2025
Sat, May 24, 2025
Fri, May 23, 2025
Thu, May 22, 2025
Wed, May 21, 2025
Tue, May 20, 2025
[ Tue, May 20th ] - 13abc
Moment of Science: Cicadas
Mon, May 19, 2025
Sun, May 18, 2025
Sat, May 17, 2025
Fri, May 16, 2025
Thu, May 15, 2025
Wed, May 14, 2025
Tue, May 13, 2025
[ Tue, May 13th ] - WSAZ
Summer science experiments
Mon, May 12, 2025
Sun, May 11, 2025

A cautious culture cost Novo its obesity lead


//science-technology.news-articles.net/content/2 .. cautious-culture-cost-novo-its-obesity-lead.html
Published in Science and Technology on by STAT   Print publication without navigation

And more biotech news updates, brought to you by The Readout.

The article from STAT News dated June 5, 2025, discusses several significant developments in the biotech industry. Novo Nordisk is set to acquire Vigil Neuroscience for $1.5 billion, aiming to bolster its neuroscience portfolio. Merck is facing challenges with its blockbuster cancer drug Keytruda, as a new study suggests it may not be as effective in certain patient populations as previously thought. Eli Lilly is expanding its manufacturing capabilities to meet the growing demand for its diabetes and obesity treatments. Lastly, REGENXBIO reported positive results from a Phase II trial of its gene therapy for Duchenne muscular dystrophy, sparking optimism about future treatments for the condition.

Read the Full STAT Article at:
[ https://www.statnews.com/2025/06/05/biotech-news-novo-nordisk-vigil-merck-eli-lilly-regenxbio-keytruda-the-readout/ ]

Publication Contributing Sources